Episodi

  • Colgate-Palmolive Q1 2026 Earnings Analysis
    May 2 2026
    **BETA FINCH PODCAST SCRIPT**

    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the latest quarterly results and what they mean for investors. I'm Alex.

    **JORDAN**: And I'm Jordan. Today we're breaking down Colgate-Palmolive's Q1 2026 earnings call, and there's quite a bit to unpack here.

    **ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN**: Absolutely. Now, Alex, Colgate had an interesting quarter - some really strong performance in certain areas, but they're also dealing with significant headwinds. Where do you want to start?

    **ALEX**: Let's kick off with the headline numbers. Colgate delivered what CEO Noel Wallace called "strong top and bottom line growth" with organic sales growth actually accelerating from Q4. They saw growth in both volume and pricing across all four categories and four of five divisions, which is pretty impressive breadth.

    **JORDAN**: That's right, and what really caught my attention was the geographic mix. Emerging markets were the star of the show, particularly Asia Pacific. Wallace mentioned that these are regions where Colgate's global brands have higher market shares and greater scale advantages, so they're doubling down on investments there.

    **ALEX**: Speaking of investments, they're maintaining their focus on brand equity and advertising spending, which is notable given the cost pressures they're facing. But Jordan, let's talk about the elephant in the room - that $300 million increase in expected raw material and logistics costs.

    **JORDAN**: Yeah, this is where things get interesting from a margins perspective. They had to revise their gross margin outlook downward because of these cost pressures. CFO Stanley Sutula broke it down - about two-thirds of that $300 million hit is from raw materials, one-third from logistics. The big culprits? Oil byproducts like resins and petrochemicals, with spending in those areas expected to be up more than 20% year-over-year.

    **ALEX**: And they're assuming crude oil at around $110 for their planning purposes. But here's what I found encouraging - despite these headwinds, they reaffirmed their full-year guidance for both top and bottom line growth. How are they managing to do that?

    **JORDAN**: It comes down to what Wallace calls their "flexible P&L model." They're offsetting these cost pressures through several levers: revenue growth management, or RGM, productivity initiatives, and they just announced an acceleration of their Strategic Growth and Productivity Program - or SGPP.

    **ALEX**: Let's dig into that SGPP announcement because it's pretty significant. They're now targeting $200 million to $300 million in annualized savings, with most of those savings hitting in 2027 and 2028. Wallace emphasized this isn't an extension of the program - it's still completing by end of 2028 - but they've identified additional opportunities.

    **JORDAN**: Right, and Sutula explained that the strong execution from their teams allowed them to reach the high end of their initial targets, plus they found new ways to simplify operations and enhance efficiency. I like that they're being proactive about organizational structure and reducing complexity.

    **ALEX**: Now, the regional performance was really telling. Asia Pacific was a standout, with improvements in both China through their Hawley & Hazel business and strong performance in India. Wallace mentioned they're not "completely out of the woods" in China yet, but the interventions they've made - accelerated innovation, better omnichannel execution - are starting to pay off.

    **JORDAN**: Latin America also had another strong volume quarter with mid-single-digit growth. Wallace was particularly enthusiast

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    8 min
  • Altria Q1 2026 Earnings Analysis
    Apr 30 2026
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear, actionable insights. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're diving into Altria Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including a CEO transition and some fascinating market dynamics in both cigarettes and nicotine pouches.

    **ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Absolutely. Now, let's talk numbers first. Altria delivered a solid start to 2026 with adjusted diluted EPS growing 7.3% in Q1. They're maintaining their full-year guidance of $5.56 to $5.72 per share, which represents 2.5% to 5.5% growth.

    **ALEX:** That's a strong performance, but what really caught my attention was the underlying story about consumer behavior. Jordan, can you break down what's happening in the cigarette market?

    **JORDAN:** Sure thing. So there are two major trends colliding here. First, we're seeing moderation in the e-vapor category - particularly those illicit flavored disposable products that have been stealing cigarette smokers for years. Federal and state enforcement is finally having an impact, and it looks like the category may have hit a saturation point.

    **ALEX:** Which is helping cigarette volumes, right? They declined only 4% when adjusted for trade inventory movements, compared to much steeper declines we've seen in recent years.

    **JORDAN:** Exactly. But here's the fascinating part - all of this volume improvement is happening in the discount segment, not premium. Consumers are under serious economic pressure. Gas prices spiked, inflation is still biting, and people are trading down to cheaper brands.

    **ALEX:** And Altria is capturing that trade-down with their Basic brand. The numbers here are pretty impressive - Basic grew 2.4 share points year-over-year in the discount segment. Meanwhile, Marlboro actually lost 1.4 share points overall but gained in the premium segment specifically.

    **JORDAN:** That's the beauty of their portfolio strategy. They're essentially playing both ends of the market. When premium smokers stay loyal, Marlboro captures them. When economic pressure forces people to trade down, Basic is there waiting.

    **ALEX:** Now let's talk about the growth story - oral nicotine pouches. This category is absolutely exploding. Jordan, what's happening with their on! brand?

    **JORDAN:** The oral nicotine pouch segment now represents 58% of the total oral tobacco category - that's remarkable growth. Altria's on! portfolio shipped nearly 18% more volume, hitting over 46 million cans in Q1. They launched on! PLUS nationwide in March, and it's already in about 100,000 stores.

    **ALEX:** What makes on! PLUS special?

    **JORDAN:** Two things: it's the first and only product authorized under the FDA's pilot program for nicotine pouches, which should give them a regulatory advantage. And they're marketing it as "the softest pouch on the planet" using their proprietary NICOSILK technology. They're really trying to differentiate on the user experience.

    **ALEX:** Speaking of the FDA, there was interesting commentary about the regulatory environment. CEO William Gifford - and by the way, this was his final earnings call - was pushing hard for the FDA to streamline authorizations for e-vapor products.

    **JORDAN:** Right, and his logic makes sense. The e-vapor category is still about 70% illicit products. Gifford argued that faster authorizations combined with sustained enforcement could create a compliant marketplace where authorized manufacturers can serve adult consumers with quality products.

    **ALEX:** Let's talk about that CEO transition. Gifford is stepping d

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    9 min
  • Coca-Cola Q1 2026 Earnings Analysis
    Apr 28 2026
    # Beta Finch Podcast Script: Coca-Cola Q1 2026 Earnings

    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're breaking down Coca-Cola's Q1 2026 earnings - and folks, this was a strong start to the year for the beverage giant.

    Before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN**: Thanks Alex. And what a quarter this was for Coca-Cola! Let me hit you with the headline numbers first. The company delivered 10% organic revenue growth with 3% volume growth across all segments. That's particularly impressive when you consider the challenging macro environment we're seeing globally.

    **ALEX**: Absolutely. And Jordan, what really caught my attention was the earnings per share performance - 18% growth to 86 cents per share on a comparable basis. That's solid double-digit growth that beat expectations. CEO Henrique Braun seemed pretty confident about their "balanced growth algorithm" approach.

    **JORDAN**: Right, and that's a key theme throughout this call - this idea of balancing volume growth with price/mix improvements. They managed 3% volume growth and 2% price/mix growth in Q1, which Braun described as exactly the kind of balanced approach they're targeting. He mentioned they might see this flip to 2% volume and 3% price/mix in other quarters, but the goal is maintaining that balance.

    **ALEX**: Now, there were some interesting regional dynamics here. North America showed solid performance with volume and value share gains, but they had some headwinds from Easter timing and category mix issues, particularly with packaged water and production constraints on Topo Chico and Fairlife.

    **JORDAN**: And speaking of Fairlife - which investors have been watching closely - Braun confirmed that the Webster facility capacity is coming online in Q2 as planned, which should help address those production constraints. That's a key capacity expansion for their growing dairy business.

    **ALEX**: Let's talk about some of the geographic highlights because this really shows Coke's global reach. In Latin America, they gained value share despite challenges in Mexico from the sugar tax that was implemented at the beginning of the year. But Brazil and Central America more than offset those declines.

    **JORDAN**: And in EMEA - that's Europe, Middle East, and Africa - they gained value share and grew volume across all operating units, despite some obvious challenges from the Middle East conflict. Braun noted that while they grew volume for the quarter overall, volumes did decline in March after the onset of that conflict.

    **ALEX**: The Asia Pacific region is particularly interesting from a strategic standpoint. They grew volume across all operating units despite cycling a tough comparison from the prior year. But Jordan, the margin story there was concerning - operating margins compressed almost 10 percentage points.

    **JORDAN**: That's right Alex, and CFO John Murphy addressed this directly. About two-thirds of that margin compression was due to a one-time inventory issue, particularly phasing of juice inventory costs in China. They also had commodity pressures in tea and coffee businesses. Murphy emphasized this was largely a Q1 anomaly and they expect improvement as the year progresses.

    **ALEX**: One thing that really stood out in the Q&A was the discussion around innovation and consumer centricity. Braun talked about their "4 I's" approach - insight, innovation, intimacy, and integrated execution. They highlighted the success of Coca-Cola Zero-Zero in Europe, which targets consumers who want to reduce caffeine intake in the evening.

    **JORDAN**: That's

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    8 min
  • 3M Q1 2026 Earnings Analysis
    Apr 21 2026
    **BETA FINCH PODCAST SCRIPT**

    ---

    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into 3M's first quarter 2026 results. Jordan, this was quite an interesting call from the industrial giant.

    JORDAN: Absolutely, Alex. And before we jump in, I want to remind our listeners that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Thanks for that, Jordan. Now, let's talk 3M. The headline numbers were pretty solid - earnings per share of $2.14, up mid-teens from last year, and operating margins improved 30 basis points to 23.8%. But the revenue story was a bit more nuanced, wasn't it?

    JORDAN: That's right. Organic growth came in at just 1.2% for the quarter, which CEO Bill Brown called a "light start to the year." But here's what caught my attention - orders were up over 10%, and backlog grew double digits both sequentially and year-over-year. That's typically a good leading indicator.

    ALEX: And Brown seemed pretty confident about that acceleration, didn't he? He kept emphasizing that they expect growth to pick up in Q2 and the back half of the year. What do you think is driving that optimism?

    JORDAN: Well, there are a few factors. First, they're seeing strong momentum in what they call their "commercial excellence" initiatives - basically better sales effectiveness and reduced customer churn. They've already captured $80 million of new business against a three-year target of $100 million. Plus, they're launching new products at an accelerated pace - 84 new products in Q1, up 35% from last year.

    ALEX: I was fascinated by their AI initiatives. They mentioned using AI tools to analyze sales data and create customized coaching plans for sales managers. And there's this "Ask 3M Company" AI assistant that helps customers find solutions. It feels like they're really embracing technology to drive growth.

    JORDAN: Absolutely. And speaking of technology, one of the most interesting parts of the call was their discussion of the data center business. They highlighted expanded beam optics - or EBO - which is apparently a high-performance optical connector for data centers. With hyperscaler validation and what they called a "billion-dollar-plus addressable market," they're investing to more than double capacity.

    ALEX: That ties into the broader AI and data center boom we're seeing across the market. But let's talk about some of the challenges. They mentioned softness in consumer electronics and automotive, which affected about 40% of their portfolio.

    JORDAN: Right, and this is where the story gets interesting from a portfolio management perspective. Brown talked about how roughly 60% of their businesses showed strength, while 40% faced macro headwinds. In electronics, they saw strong performance in semiconductors and data centers, but consumer electronics was soft due to what they called "industry-wide memory chip issues."

    ALEX: And then there was this interesting discussion about pre-buying. CFO Anurag Maheshwari and Brown acknowledged that some of the strong order growth might have been customers buying ahead of price increases. How significant do you think that was?

    JORDAN: It's hard to quantify, but they seemed to suggest it was a factor. They're implementing price increases due to rising oil costs - about $125 million of cost impact that they're offsetting with roughly 50 basis points of additional pricing. Brown mentioned they learned from their experience with tariffs and are moving much faster on pricing this time.

    ALEX: Let's talk about their operational transformation. They're really reshaping this company, aren't they? They mentioned reducing their manufacturing footprint to below 100 facilities.

    JORDAN: That's a major shift. They closed or announ

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    9 min
  • PepsiCo Q1 2026 Earnings Analysis
    Apr 16 2026
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that matter. I'm Alex, and I'm here with my co-host Jordan to break down PepsiCo's Q1 2026 earnings call. Jordan, this was quite an interesting quarter with some geopolitical backdrop we don't usually see.

    **JORDAN**: Absolutely, Alex. And before we jump into the numbers, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **ALEX**: Thanks, Jordan. Now, let's talk PepsiCo. The big headline here is that they're showing sequential improvement across their business units, particularly in North America Foods, which has been a challenge area. They maintained their organic revenue guidance of 2% to 4% for the year, with expectations to hit the higher end in the back half.

    **JORDAN**: Right, and what's fascinating is how they're navigating this Iran conflict situation. CFO Steve Schmitt was pretty transparent about it - they have 6 to 12-month hedging programs in place, and surprisingly, they're not seeing major supply chain disruptions. In fact, CEO Ramon Laguarta mentioned they might actually have better supply chain resilience than some competitors, especially in the food business.

    **ALEX**: That's a great point about competitive advantage during tough times. Let's break down the segment performance. The North America Foods business, which has been under pressure, showed 2% volume growth in Q1. Jordan, this seems like a real turnaround story.

    **JORDAN**: It really is, Alex. What's impressive is the scale of this turnaround - they added 300 million new consumption occasions in Q1 compared to the same period last year. That's massive. Ramon talked about this being a "holistic commercial strategy" involving better value propositions, more shelf space, brand restaging for Lay's and Tostitos, and accelerated innovation in what they call "permissible and functional" products.

    **ALEX**: And they're seeing results in market share too, right? They mentioned gaining positive share in both volume and value recently, which had been a key performance indicator they set for themselves.

    **JORDAN**: Exactly. The away-from-home business is growing at 3x the company average, and their permissible portfolio brands like SunChips and Smartfood are seeing double-digit growth in some cases. But here's what I found most interesting - their costs for North America Foods actually went *down* in Q1 while they're investing more. That speaks to their productivity initiatives really paying off.

    **ALEX**: That productivity story is huge. Let's talk about the beverage side - PBNA grew 9% total, which is pretty impressive.

    **JORDAN**: Yeah, but it's a mixed bag when you dig deeper. The headline 9% growth includes about 7 points from new platforms and acquisitions like Poppi and expanded energy drink distribution. The organic growth was around 2%. They're still dealing with a case pack water transition that pressured volumes, but Ramon expects that to turn positive in coming quarters.

    **ALEX**: One thing that stood out from the Q&A was the discussion around SNAP benefit restrictions and GLP-1 drugs. These are newer headwinds the industry is watching closely.

    **JORDAN**: True, eight states began SNAP restrictions in Q1, mainly affecting beverages and candy. But Steve Schmitt said it's too early to draw conclusions. What's more interesting is how they're positioning for these secular changes - they're doubling down on innovation in functional and permissible products, which could actually benefit from health-conscious trends.

    **ALEX**: The international business seems to be firing on all cylinders. Ramon mentioned they haven't seen demand impact from the Iran conflict and are actually accelerating in

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    8 min
  • Abbott Laboratories Q1 2026 Earnings Analysis
    Apr 16 2026
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Abbott Laboratories' Q1 2026 earnings call. Jordan, this was a pretty significant quarter for Abbott - they just closed their acquisition of Exact Sciences back in March.

    **JORDAN**: Absolutely, Alex. And before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **ALEX**: Thanks for that reminder. So let's talk numbers first. Abbott reported adjusted earnings per share of $1.15 for Q1, which was right in line with their guidance despite some headwinds. Revenue-wise, they're now reporting what they call "comparable growth" of 3.7%, which includes Exact Sciences in both current and prior year numbers.

    **JORDAN**: That comparable growth metric is really interesting, Alex. CEO Robert Ford explained they're doing this to give investors a cleaner apples-to-apples view of the combined business. It's similar to what they did during COVID when they separated out COVID sales, or when they acquired St. Jude. The goal is transparency.

    **ALEX**: Right, and looking forward, they've updated their full-year guidance to 6.5% to 7.5% comparable sales growth. But here's what caught my attention - their adjusted EPS guidance midpoint dropped from $5.68 to $5.48. That $0.20 dilution is directly from the Exact Sciences acquisition, which was expected.

    **JORDAN**: Let's break down the business segments because there were some really interesting dynamics. Medical Devices was the star performer with 8.5% growth. The Electrophysiology business grew 13%, and get this - they had earlier-than-planned approvals for two new pulsed field ablation catheters.

    **ALEX**: Those PFA catheters are a big deal, Jordan. The Volt PFA catheter helped drive 14% growth in the U.S., while the TactiFlex Duo catheter contributed to mid-teens growth in Europe. Ford seemed pretty bullish about acceleration in the EP business as these launches broaden.

    **JORDAN**: And speaking of acceleration, the continuous glucose monitoring business had some interesting dynamics. CGM sales were $2 billion but only grew 7.5% due to an international tender delay and some tough comparisons from last year's shelf restocking. But management expects a return to double-digit growth in Q2.

    **ALEX**: That's a key point. During the Q&A, Ford was asked about concerns that the CGM market might be saturated. His response was fascinating - he said they estimate 70 to 80 million people globally should be on CGM, but the current market is only 10 to 12 million people. That's massive underpenetration.

    **JORDAN**: He also mentioned some upcoming catalysts, including expected CMS coverage for type 2 non-insulin patients, which could add close to 10 million people who currently don't have coverage. Ford was very clear he hadn't baked that into guidance, so it could be upside if it materializes.

    **ALEX**: Now let's talk about the Exact Sciences integration. This was really the elephant in the room. Ford named Jake Orville to lead that business, reporting directly to him. The Cologuard business grew 13% on a comparable basis, with mid-teens growth of the core Cologuard product.

    **JORDAN**: What struck me was Ford's long-term vision here. He doesn't see this as just a one-product deal, but as a beachhead into the entire cancer diagnostics space - screening, therapy selection, and MRD testing. He pointed out that about 50 million Americans aren't up to date with colorectal cancer screening.

    **ALEX**: And internationally, Ford said it's very underpenetrated. Abbott brings established regulatory and distribution relationships that could really accelerate international expansion. He even mentioned traveling to

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    9 min
  • Philip Morris International Q4 2025 Earnings Analysis
    Mar 21 2026
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Philip Morris International's Q4 2025 earnings call. Now before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN**: Thanks Alex! And what a call this was from Philip Morris. They absolutely crushed it in 2025, delivering what CEO Jacek Olczak called "another outstanding year." We're talking about their fifth consecutive year of positive volumes, driven primarily by their smoke-free products business.

    **ALEX**: Right, and the numbers really tell the story here. Philip Morris hit over $40 billion in total net revenues for 2025, with smoke-free products now representing 41.5% of that - nearly $17 billion! That's a massive shift from where they were just a few years ago.

    **JORDAN**: The growth trajectory is impressive. Smoke-free product volumes grew 12.8%, with IQOS leading the charge at 11% growth. But here's what caught my attention - their ZYN nicotine pouches in the US grew shipments by 37%, despite supply constraints. That's reaching 11.9 billion pouches, making up about 7% of their total smoke-free volume.

    **ALEX**: And let's talk profitability because that's where this story gets really interesting. Their smoke-free gross margin hit 69.5%, which is now four percentage points higher than their combustible business. CFO Emmanuel Babeau made it clear that this improving profitability mix is a key driver of their overall margin expansion.

    **JORDAN**: Speaking of margins, they delivered 140 basis points of organic margin expansion to reach 40.4% adjusted operating margin. That's while they're still investing heavily in marketing and brand building for their smoke-free portfolio. It shows real operating leverage in the business model.

    **ALEX**: Now, the guidance for 2026 is where things get particularly interesting. They're forecasting organic net revenue growth of 5-7%, which might seem modest compared to recent years, but there are some specific headwinds they're navigating.

    **JORDAN**: Exactly. The big story is Japan, where they're facing significant excise tax increases on heated tobacco products - we're talking 50-100 yen per pack, which could be 10-20% of current retail prices. This creates an asymmetry where heated tobacco gets hit first, before cigarettes face similar increases in 2027.

    **ALEX**: And in the US, there's the ZYN inventory normalization. They estimate there are about 25 million cans of surplus inventory in the downstream supply chain that needs to work through, likely in Q1. But the underlying demand story remains strong - ZYN maintained about 61.5% volume share in the US nicotine pouch category.

    **JORDAN**: What I found fascinating in the Q&A was the discussion around ZYN Ultra, their higher-strength nicotine pouch that's pending FDA approval. Olczak was pretty direct - they have readiness to launch "essentially as we speak," and they're expecting some movement this summer, though he admitted he doesn't have a great track record forecasting the FDA!

    **ALEX**: [Laughs] At least he's honest about that! But you can tell they're frustrated with the regulatory environment. When asked about New York's proposed excise tax on nicotine pouches, Olczak called it "counterproductive to the health benefits" and "the wrong idea."

    **JORDAN**: The international expansion story is really compelling too. They're now in 106 markets with smoke-free products, and some of these new launches are showing impressive traction. Taiwan caught my eye - they hit 4% market share in just a few weeks after launch. That's remarkable penetration for a new market entry.

    **ALEX**: And they're not just focused on IQOS any

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    8 min
  • Procter & Gamble Q2 2026 Earnings Analysis
    Mar 21 2026
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into Procter & Gamble's Q2 2026 earnings call. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN**: Thanks Alex. And what a quarter to unpack! P&G just reported what management called their "softest quarter of the fiscal year," but there's actually a lot more optimism here than that headline might suggest.

    **ALEX**: Absolutely. Let's start with the numbers, Jordan. Organic sales were flat year-over-year, which sounds underwhelming until you understand the context. They had some major base period disruptions - remember those port strikes and hurricanes last October that caused all that inventory loading?

    **JORDAN**: Right, and CFO Andre Schulten was very clear about this. The biggest impacts hit baby care, feminine care, and family care - all concentrated in the U.S. market. But here's the interesting part: the rest of P&G's business outside the U.S. actually grew nearly 3%. That's a pretty solid foundation.

    **ALEX**: That's a great point. When you look at the regional breakdown, you see some real bright spots. Latin America grew 8%, Greater China was up 3% - which is impressive given the challenging consumer environment there. Europe's enterprise markets grew 6%. It really was a U.S.-centric slowdown.

    **JORDAN**: And speaking of China, I loved CEO Shailesh Jejurikar's example about their Pampers Prestige innovation. They tapped into this deep cultural insight about Chinese parents wanting the best for their babies, and literally incorporated silk - this symbol of luxury for over 2,000 years - into their diapers. It's driving double-digit growth and they've gained nearly three points of market share.

    **ALEX**: That's exactly the kind of consumer-centric innovation P&G is doubling down on. Jejurikar talked extensively about what he called "the next important phase of constructive disruption." They're not just tweaking around the edges - they're fundamentally reimagining how a CPG company operates in today's fragmented media landscape.

    **JORDAN**: The technology transformation really stood out to me. They've built this massive data lake with petabytes of consumer information, AI-powered tools for product development, and supply chain systems that can react autonomously to demand signals. But Jejurikar was realistic about the timeline - he said it'll take 12 to 18 months to get this "future evenly distributed" across the company.

    **ALEX**: Let's talk margins for a second. Core EPS came in at $1.88, flat with last year. But they delivered 270 basis points of productivity improvements, which they reinvested back into innovation and marketing. That's classic P&G - they're not letting a tough quarter derail their long-term investment strategy.

    **JORDAN**: And they're maintaining all their full-year guidance, which shows real confidence. Organic sales growth of flat to plus 4%, core EPS growth of flat to plus 4%. They're basically saying "trust us, the back half is going to be much stronger."

    **ALEX**: The Q&A session revealed some interesting dynamics too. When analysts pressed about U.S. market share losses, Schulten was pretty direct - they have work to do to recover share, but they're already seeing progress in categories like family care and laundry where they've made those innovation interventions.

    **JORDAN**: I thought the discussion about e-commerce was fascinating. One analyst pointed out that Amazon is driving 60-80% of growth in P&G's categories. Jejurikar's response was telling - they're being very deliberate about winning in fast-growing channels, and in some markets like India, their e-commerce share

    This episode includes AI-generated content.
    Mostra di più Mostra meno
    8 min